



AeoNose for Covid-19 screening

Presentation for GGD Amsterdam, October 2020

Strictly Confidential



Agenda

- AeoNose exhaled-breath analysis
 - Features
 - Status
- Pilot results for Covid-19
- Proposed approach for GGD Amsterdam
- Discussion items
- Next steps



Features AeoNose

- Point-of-Care device
 - 5 minutes breathing, 10 minutes rinsing, immediate classification
 - Portable, battery-powered
 - CE, ISO 13485
- Non-invasive
- Disposable mouth piece & filters
- iPad controlled: communicating with data center





Point-of-Care exhaled-breath analysis




Status AeoNose

- 20 years of know-how in eNose technology, 10 years in medical applications,
- Solid approach
- > 90 papers & conference contributions on various indications,
- Finishing-up multi-center validation studies on lung cancer and colorectal cancer,
- Pilot study on Covid-19
- 50 devices in stock
- Production (outsourced), CE, ISO 13485



Pilot study results for Covid-19

- Clinical study at MUMC
- 219 participants (MUMC employees)



- Next: validating results pilot study including classifying blind samples



Proposed approach for GGD Amsterdam

- Setting-up task force (if not available already)

- Epidemiologist
- Virologist / microbiologist
-
- Academic back-up

- Protocol

- 'Golden' standard
- Sample size
- Follow-up participants
- Preferably: approval by METC

- Building algorithm

- Collecting breath samples
- Data analysis
- Check with blind samples (validation)



Proposed approach for GGD Amsterdam

- Timeframe
 - Protocol + METC 1 week
 - Breath sampling & building algorithm 4 weeks
- Dedicated training and support available from The eNose Company



Discussion items

- Sensitivity & specificity required (sensitivity swab-PCR $\pm$ 75%)
- Approval by authorities ?
- Numbers of devices & consumables needed
- Costs involved



Next steps

- How do we proceed from here?